MARK is a family of kinases that is known for its involvement in establishing cell polarity and in phosphorylating tau protein during Alzheimer neurodegeneration. Expression of MARK causes the phosphorylation of MAPs at their KXGS motifs, thereby detaching MAPs from the microtubules and thus facilitating the transport of particles. This occurs without impairing the intrinsic activity of motors because the velocity during active movement remains unchanged. In primary retinal ganglion cells, transfection with tau leads to the inhibition of axonal transport of mitochondria, APP vesicles, and other cell components which leads to starvation of axons and vulnerability against stress. This transport inhibition can be rescued by phosphorylating tau with MARK.
Target |
MARK1 |
Reactivity |
Human, Mouse |
Host |
Rabbit |
Clonality |
Polyclonal |
Tested Applications |
WB, IHC |
Recommended dilutions |
Optimal dilutions/concentrations should be determined by the end user. |
Immunogen |
KLH-conjugated synthetic peptide between 6-40 amino acids from the N-terminal region of human MARK1. |
Purification |
Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. |
Isotype |
IgG |
Conjugation |
Unconjugated |
Storage |
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Swiss Prot |
Q9P0L2
|
NCBI Accession |
NP_061120.3
|
Buffer |
PBS containing 0.09% sodium azide. |
UNSPSC Code |
12352203 |
Availability |
Shipped within 5-10 working days. |
Note |
This product is for research use only. |